Zhang et al. showed that the synthetic peptide R11-p53c can be effectively and preferentially delivered into bladder cancer cells, resulting in the reactivation of the p53 gene and inhibition of tumor growth. The gene discussed is TP53; the disease is urinary bladder carcinoma.